Description
The Department of Veterans Affairs (VA) is seeking a sole source firm-fixed price contract for the provision of Pluvicto (Lutetium Lu 177 Vipivotide Tetraxetan), a radioactive therapy treatment for Prostate-specific Membrane Antigen-Positive Metastatic Castration-Resistant Prostate Cancer (PSMA-Positive mCRPC). The contract will be awarded to Advanced Accelerator Applications USA under the authority of FAR 8.405-6(a)(1)(B). Interested parties may submit a capability statement to identify their interest and capability to respond to the requirement. The statement should include a tailored capability statement, SAM UEI number, organization name, address, point of contact, and size and type of business.
• The contract is for a firm-fixed price.
• The contract is for the provision of a radioactive therapy treatment.
• The treatment is for Prostate-specific Membrane Antigen-Positive Metastatic Castration-Resistant Prostate Cancer (PSMA-Positive mCRPC).
• Interested parties must submit a capability statement.
• The statement should include a tailored capability statement, SAM UEI number, organization name, address, point of contact, and size and type of business.